Literature DB >> 19117008

Different roles of N- and C- termini in the functional activity of FGF21.

Radmila Micanovic1, David W Raches, James D Dunbar, David A Driver, Holly A Bina, Craig D Dickinson, Alexei Kharitonenkov.   

Abstract

Fibroblast growth factor 21 is a member of endocrine FGFs subfamily, along with FGF19 and FGF23. It is emerging as a novel regulator with beneficial effects on a variety of metabolic parameters, including glucose and lipid control. FGF21 activity depends on membrane protein betaKlotho that physically complexes with various FGF receptors, thus conferring them the ability to bind FGF21 and activate downstream signaling pathways. FGF21, like other FGFs, folds to a beta-trefoil-like core region, with disordered N- and C-termini. In order to investigate their role in the activity of FGF21, we have constructed a series of deletion mutants and tested them for their ability to (1) bind betaKlotho, analyzed by surface plasmon resonance spectroscopy (2) signal through MAPK phosphorylation and inhibit apoptosis in 3T3-L1/betaKlotho fibroblasts (3) stimulate GLUT1 mRNA upregulation and glucose uptake in 3T3-L1 adipocytes. Binding studies with betaKlotho revealed that the interaction with the co-receptor involves the C-terminus, as progressive removal of amino acids from the carboxy end decreased affinity for betaKlotho. By contrast, removal of up to 17 amino acids from the N-terminus had no effect on the interaction with betaKlotho. Terminal deletions had greater effect on function, as deletions of six amino acids from the amino-terminus and only four from the carboxy-terminus each significantly impacted activity (10-fold). Of the extreme terminal truncations, with no detectable activity, DeltaN17 acted as competitive antagonist while DeltaC20 did not. Our structure/function studies show that the C-terminus is important for betaKlotho interaction whereas the N-terminus likely interacts directly with FGF receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19117008     DOI: 10.1002/jcp.21675

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  51 in total

1.  Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor.

Authors:  Regina Goetz; Mutsuko Ohnishi; Serkan Kir; Hiroshi Kurosu; Lei Wang; Johanne Pastor; Jinghong Ma; Weiming Gai; Makoto Kuro-o; Mohammed S Razzaque; Moosa Mohammadi
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

Review 2.  Fibroblast growth factor 21 in chronic kidney disease.

Authors:  Paulo Giovanni de Albuquerque Suassuna; Rogério Baumgratz de Paula; Hélady Sanders-Pinheiro; Orson W Moe; Ming-Chang Hu
Journal:  J Nephrol       Date:  2018-11-14       Impact factor: 3.902

3.  Structures of ligand-occupied β-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity.

Authors:  Ekaterina S Kuzina; Peter Man-Un Ung; Jyotidarsini Mohanty; Francisco Tome; Jungyuen Choi; Els Pardon; Jan Steyaert; Irit Lax; Avner Schlessinger; Joseph Schlessinger; Sangwon Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-03       Impact factor: 11.205

4.  Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis.

Authors:  Eleni M Domouzoglou; Eleftheria Maratos-Flier
Journal:  Am J Clin Nutr       Date:  2011-02-23       Impact factor: 7.045

Review 5.  Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis.

Authors:  Kathleen R Markan; Matthew J Potthoff
Journal:  Semin Cell Dev Biol       Date:  2015-09-30       Impact factor: 7.727

6.  Circulating fibroblast growth factor 21 is reduced, whereas its production is increased in a fat depot-specific manner in cold-acclimated rats.

Authors:  Diane M Sepa-Kishi; Rolando B Ceddia
Journal:  Adipocyte       Date:  2018-09-20       Impact factor: 4.534

Review 7.  Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis.

Authors:  Lucas D BonDurant; Matthew J Potthoff
Journal:  Annu Rev Nutr       Date:  2018-05-04       Impact factor: 11.848

8.  Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action.

Authors:  Caslin A Gilroy; Stefan Roberts; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2018-03-15       Impact factor: 9.776

9.  FGF21 and glycemic control in patients with T1D.

Authors:  Simone Rosell Rask; Troels Krarup Hansen; Mette Bjerre
Journal:  Endocrine       Date:  2019-08-01       Impact factor: 3.633

Review 10.  Fibroblast growth factor 21: an overview from a clinical perspective.

Authors:  Mikael Rydén
Journal:  Cell Mol Life Sci       Date:  2009-03-11       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.